AUS
NZ
UK
CA
USA
IND
On July 27, 2026, Edwards Lifesciences Corp revealed that its Chief Executive Officer, Bernard J. Zovighian, executed several transactions involving the company’s common stock. These included the sale of shares through a trust and acquisitions of additional shares via direct ownership and an indirect 401(k) plan. The disclosure, submitted through a Form 4 statement of changes in beneficial ownership, offers insight into the executive trading activities at the medical device company.
Key Points
- NYSE ticker: EW
- CEO Bernard Zovighian completed multiple stock transactions on July 27, 2026
- Zovighian sold 2,920.5511 shares at $83.9342 per share via a trust arrangement
- Post-transactions, Zovighian directly owned 98,845 shares and held indirect stakes through a trust and 401(k) plan
Summary of CEO Stock Transactions on July 27, 2026
According to Edwards Lifesciences’ regulatory filing, CEO Bernard J. Zovighian engaged in multiple equity transactions involving the company’s common stock on July 27, 2026. These trades altered his beneficial ownership position, reflecting both acquisitions and dispositions of shares during the reporting period.
Zovighian serves as both director and CEO of Edwards Lifesciences. The transactions, all executed on the same date, modified his direct and indirect ownership in the company. The filing complies with Section 16 of the Securities Exchange Act of 1934, ensuring transparency of insider trading activities.
Share Sale Executed Through Trust Structure
The largest transaction disclosed was the sale of 2,920.5511 shares at $83.9342 each, conducted through a trust arrangement representing indirect ownership. After this sale, Zovighian’s indirect holdings via the trust amounted to 8,915.6499 shares. This transaction was recorded on July 27, 2026, and classified as a sale in the regulatory documents.
Utilizing a trust for share disposition is a common practice among executives managing their portfolios. The disclosure clarifies the nature of indirect beneficial ownership, helping investors and regulators understand the various structures through which company leaders hold equity. The sale price reflects market conditions on the transaction date.
Direct Acquisitions and Additional Trust Holdings
Alongside the share sale, the filing shows that Zovighian acquired 319.6499 shares directly, increasing his direct beneficial ownership to 98,845 shares. These were coded as grant transactions with a $0.0000 price, indicating equity compensation or similar non-market purchases.
Additionally, Zovighian acquired 319.6499 shares indirectly through a trust, raising the trust’s holdings to 11,836.201 shares. Together with the sale, these transactions highlight a strategic approach to managing ownership across multiple vehicles, reflecting changes in his total beneficial stake in Edwards Lifesciences.
401(k) Retirement Plan Holdings and Overall Ownership
The disclosure also notes that Zovighian holds 3,733.5603 shares indirectly through a 401(k) retirement plan. Such holdings are typical for executives and represent long-term investment in company stock via qualified retirement accounts.
Combining direct ownership, trust holdings, and 401(k) shares, the filing offers a comprehensive picture of Zovighian’s equity stake. This diversified ownership structure is common among senior executives, reflecting a mix of compensation-related and personal investment positions. Each category is itemized separately to maintain transparency regarding the forms of beneficial ownership.
Transaction Classification and Regulatory Compliance
The filing uses standard SEC transaction codes: "G" for grants and "S" for sales. These codes enable quick identification of the transaction types. Zovighian’s activities included equity compensation grants and a direct sale of shares via his trust.
Such regulatory disclosures promote market transparency and help prevent conflicts of interest. By submitting detailed statements of changes in beneficial ownership, executives provide investors with timely insights into leadership trading activities. The documentation specifies dates, share amounts, prices, and ownership forms, creating a clear audit trail.
Understanding Beneficial Ownership and Disclosure Scope
The filing clarifies that the reported transactions represent changes in beneficial ownership on July 27, 2026, and may not encompass all Edwards Lifesciences securities held by Zovighian. This standard disclaimer indicates the filing is a snapshot of activity on a specific date rather than a full inventory of his holdings.
Beneficial ownership includes direct holdings and situations where a person controls voting or disposition rights, even if legal title is held elsewhere. The detailed breakdown of direct, trust, and 401(k) holdings illustrates the complexity of executive shareholding and the regulatory requirement to disclose all forms of beneficial interest, ensuring transparency across ownership structures.
Edwards Lifesciences Overview and Market Position
Edwards Lifesciences Corp is a leading medical device company specializing in cardiovascular, structural heart disease, and critical care monitoring technologies. CEO Bernard Zovighian plays a key role in guiding the company’s strategic and operational direction. Executive shareholdings like his are closely watched by investors as indicators of management confidence and alignment with shareholder interests.
The filing does not provide forward-looking statements or strategic outlooks. Instead, it documents historical transactions and resulting ownership changes. The sale price of $83.9342 per share offers a valuation reference as of July 27, 2026, without commentary on market trends or transaction rationale.
Investor Insights from the Disclosure
The Form 4 filing delivers transparent information on executive equity transactions, a vital aspect of corporate governance and regulatory adherence. The disclosed trades—including acquisitions and a sale—demonstrate Zovighian’s active management of his stake in Edwards Lifesciences. Investors may interpret such activity as signals of management’s confidence or strategy regarding company value.
Compliance with securities regulations mandates that officers and directors report changes in beneficial ownership. The immediate impact of these transactions on share price is not evident from the filing alone. Investors seeking broader context—such as whether trades were routine equity compensation or discretionary sales—should consult additional company disclosures or investor relations resources.
